Pioglitazone (Piog) activates peroxisome proliferator activated receptor-γ (PPARγ) and is widely used in clinic for the treatment of diabetes mellitus. PPARγ in various tissues has the essential regulatory role of multiple metabolic function, suggest that PPARγ signaling may contribute to aging processes. However, little is known about the consequences of Piog on aging in aged animal models. We used apolipoprotein E deficient (apoE −/− ) mice model to evaluate the effects of Piog on aging-related disorders. Our results showed that long-term and lowdose Piog treatment significantly reduced aortic atherosclerosis, aging-related renal glomerulosclerosis and interstitial fibrosis, and hepatic steatosis, while improved the dermis in skin atrophy, compared to the control group. These morphological alterations were linked to the role of Piog, including regulation of plasma cholesterol and triglycerides (TG) levels, increased antioxidant superoxide dismutase (SOD) activity and decreased myeloperoxidase (MPO) activity. Moreover, accompanied with up-regulation of PPARγ expression, Piog had obviously increased the mRNA levels of anti-aging genes Sirtuin1 and Klotho, decreased the p53 protein level, and altered the expression of several genes involving cholesterol excretion, TG biosynthesis and inflammation in the liver. In conclusion, Piog treatment is effective to modulate the oxidative and inflammatory status, cell senescence, and lipid metabolism, contributing to attenuate several aging-related disorders in the aged apoE −/− mice, thereby maybe a promising protective therapy of aging and age-related diseases.
Introduction
Aging is characterized by a progressive loss of physiological functions and metabolic processes. Besides changes in gene expression and metabolic control, the aging rate has been associated with oxidative stress caused by high levels of reactive oxygen species (ROS) (LopezOtin et al., 2013; Davalli et al., 2016) . Because aging has a close relationship with most chronic degenerative diseases, such as atherosclerosis, diabetes, chronic renal disease and Alzheimer disease, antiaging research and the reduction of age-related diseases will benefit to enhance the quality of life and decrease the burden to the individual and society. However, the commonly applied hormone-replacement therapy has been greatly limited by its multiple side effects, therefore, some key targets of signaling pathways involved in the aging process, such as IGF-1/insulin, mTOR-S6K1, Sirtuin, p53, Klotho and apoE have been widely studied, in order to expand new therapeutic strategy and anti-aging drugs (Bao et al., 2014) .
Peroxisome proliferator activated receptor-γ (PPARγ) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. In recent decades, activation of PPARγ has been reported to regulate glucose and lipid metabolism in multiple cells, and also has some nonmetabolic effects on regulating cell cycle, inhibiting inflammation, and reducing oxidative stress, therefore, PPARγ is wellknown to play a widely role in various important tissues and organs, such as kidney, liver, brain and cardiovascular system (Ruan et al., 2008; Zardi et al., 2013; Quintanilla et al., 2014; Hamblin et al., 2009 ). Both human and rodent studies showed that PPARγ expression and activity was reduced during aging, and reduction in PPARγ signaling contributed to age-associated loss of function in rat kidney (Sung et al., 2004) or the adipose tissue in aged senescence-accelerated mice (Haramizu et al., 2011) . The Pro/Ala PPARγ-2 gene polymorphism, which related to PPARγ activity, was associated with human longevity (Barbieri et al., 2004) , and PPARγ-2 might be one of key drivers of longevity in the mouse (Argmann et al., 2009) . These suggest that activation of PPARγ signaling possibly results in the prevention against aging and age-related diseases (Ulrich-Lai and Ryan, 2013) .
Notably, some studies supported that drug treatment of increased PPARγ activity reversed age-related disturbances. PPARγ activator (2,4-TZD) could upregulate PPARγ expression, and had beneficial effect on anti-oxidative and anti-inflammatory molecules in kidney of aged rats (Sung et al., 2006) . Pioglitazone, as a high-affinity PPARγ agonist, had been found to ameliorate aging-related renal injury (Yang et al., 2009) and blunt brain aging markers in normal aging rat (Blalock et al., 2010) . However, the side effects on body mass increased, hepatotoxicity and cardiovascular complications were also reported in TZD or PPARγ agonists treatments , thus, the longterm health benefits of treatments with PPARγ agonists on aging had been eagerly explored. A recent clinic meta-analysis supported that pioglitazone treatment was the safer PPAR-targeted therapies, which shown promise in retaining efficacy while reducing potential side effects (Lincoff et al., 2007) , therefore, understanding the relative potency toward PPARγ of long-term pioglitazone as well as reducing side effects could help to identify promising therapeutic strategies for the treatment of aging-related diseases.
Aging is a consequence of a large number of genetic and environmental causes. Some genetically manipulated murine models have been found to closely reflect native aging processes in humans. Numerous population studies have identified that apolipoprotein E (apoE) polymorphism is a common risk factor for the pathogenesis of cardiovascular disorders and dementias. Since the development of apoE deficient (apoE −/− ) mice in 1992, it was gradually recognized that apoE −/− mice was characterized by a series of accelerated aging phenotypes (including weight loss, kyphosis, hypokinesis, skin atrophy etc.) and age-related diseases such as atherosclerosis and Alzheimer's disease, (Moghadasian et al., 2001; Ang et al., 2008; Bonomini et al., 2013) . Our previous study also showed that hypercholesterolemia and aortic atherosclerotic lesions were spontaneously occurred and aggravated in older apoE −/− mice even under the standard diet (Zhou et al., 2013) .
Here, we used aged apoE −/− mice as an aging animal model, to explore the anti-aging effects of pioglitazone and the underlying mechanisms. 
Materials and methods

Mice and experimental groups
Determination of biochemical parameters in plasma
Blood samples were collected from mice after overnight fasting by retro-orbital venous plexus puncture under anesthesia with 3% isoflurane at 8 weeks intervals. Plasma was immediately separated by centrifugation at 10,000 × g for 10 min at 4°C. The blood glucose (Glu), total cholesterol (TC) and triglycerides (TG) levels of fresh plasma were measured by enzymatic colorimetric assay kits (Mind Bioengineering, China). Plasma alanine aminotransferase (ALT) activity was determined using Mohum's method. Plasma creatinine level was determined using creatinine assay kit (Nanjing Jiancheng Bioengineering Institute, China). The remaining plasma was stored at − 80°C. Enzymatic colorimetric assay was conducted to determine the activity of plasma superoxide dismutase (SOD) using SOD detection kit and myeloperoxidase (MPO) activity using MPO detection kit (Nanjing Jiancheng Bioengineering Institute, China) according to the manufacturer's instructions.
Tissues collection and histochemical analyses
All mice were euthanized after orally given vehicle or Piog for 16 weeks, perfused with phosphate-buffered saline (PBS) through the left ventricle and tissues were harvested. Part of mice livers were immediately stored − 80°C for subsequent RNA extraction. Some excised liver tissue was homogenized in PBS, and total lipids were extracted using isopropanol. The amounts of TC, free cholesterol (FC), and TG were determined by enzymatic assay kits (Mind Bioengineering, China) and lipid content was normalized to liver weight. Some excised kidneys were immediately embedded in OCT (SAKURA, USA) and 8-μm-thick cryosections were detected by senescence-associated β-galactosidase (SA-β-Gal) staining kit (Beyotime Biotechnology, Nanjing, China) according to the manufacturer's instructions, briefly, the sections were fixed with SA-β-Gal fixing solution for 15 min at room temperature, washed three times in PBS, and then incubated with working solution overnight at 37°C. Positive reaction was detected as a bright blue precipitate under light microscopy, and point counting of interstitial fibrosis was performed by Image J software. Some livers, kidneys and the depilatory back skins were immersion-fixed (in 4% paraformaldehyde in 0.1 mol/L phosphate-buffered saline, pH 7.4), ethanol gradientdehydrated, paraffin embedded, and cut into 5-μm-thick sections to mount on glass slides. The sections of fixed livers and skins were stained with hematoxylin and eosin (HE) staining to observe the tissue morphology under a light microscope. The sections of fixed kidneys were prepared for Masson staining to observe the renal cortices morphology. The hearts, together with the aortic roots were embedded in OCT and quickly frozen to −20°C, then 8 μm serial cryosections were cut from the proximal aorta beginning at the end of the aortic sinus. Aortas fixed in 4% paraformaldehyde were analyzed en face. The extent of atherosclerotic lesions were determined by Oil Red O staining and quantified using Image J software, as previously described .
Real-time quantitative PCR
Mouse liver homogenates treated with Trizol reagent (Invitrogen) were used for real-time quantitative PCR (qPCR) analysis of target mRNA levels. Liver total RNA was isolated and reverse transcribed into cDNA using PrimerScript® RT reagent kit with gDNA Eraser (TaKaRa, Japan). Target mRNA levels were detected on the CFX96 Touch™ RealTime PCR Detection System (Bio-Rad, USA) by qPCR with universal PCR master mix (Invitrogen). The PCR primers for amplification of genes, including PPARγ, paraoxonase 1 (PON1), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), scavenger receptor class B type I (SR-BI), liver X receptor alpha (LXRα), ATP-binding cassette transporter A1/G8 (ABCA1/ABCG8), cholesterol 7-alpha hydroxylase (CYP7A1), cholesterol 27-alpha hydroxylase (CYP27A1), fatty acid synthase (FASN), Sirtuin 1 (Sirt1) and Klotho were listed in Table 1 . The program of RT-PCR consisted of 1 cycle at 95°C for 5 min followed by 40 cycles at 95°C for 30 s, 56.6°C-61.7°C for 30 s, and 72°C for 30 s. Mouse 18s RNA served as an internal control gene. The relative mRNA expression level for each gene was calculated using the comparative threshold cycle (ΔΔCt) method .
Western blotting analysis
Frozen livers were homogenized in RIPA lysis buffer (Beyotime D. Shen et al. Experimental Gerontology 102 (2018) 101-108 Institute of Biotechnology, China) with 1% proteinase inhibitors (Roche, Germany) and proteins were extracted for Western blotting analysis. Briefly, the liver homogenate were collected and centrifuged at 10,000 × g for 10 min at 4°C, the supernatant were determined by the Lowry method using a DC protein assay kit (Bio-Rad, USA) and appropriate amounts of proteins were loaded and separated by SDS-PAGE and Western blotting was performed as previously described . The primary antibodies included polyclonal PPARγ (1:500, Santa Cruz Biotechnology), polyclonal LXRα (1:1000, Abcam), monoclonal ABCA1 (1:1000, Abcam), monoclonal ABCG8 (1:1000, Novus Biologicals), polyclonal SR-BI (1:1000, Novus Biologicals), monoclonal p53 (1:500, Santa Cruz Biotechnology), polyclonal GAPDH (1:1000, Santa Cruz Biotechnology) and horseradish peroxidase (HRP)-conjugated secondary antibody (1:10,000, Santa Cruz Biotechnology). The signal was detected using an enhanced chemiluminescence kit (ECL, GE Healthcare, USA). The relative protein expression levels were determined by normalization to GAPDH. The band densitometry was analyzed with Image J software (NIH, USA).
Statistical analysis
The data are represented as the mean ± standard error of the mean (SEM). GraphPad Prism version 5.0 was used as statistical analyses and mapping software. The Mann-Whitney test was used to measure the statistical differences in lesion area. The other results were analyzed by Student t-test and one-way ANOVA followed by a post-hoc NewmanKeuls Multiple Comparison Test between the groups. A value of P < 0.05 was considered to be statistically significant.
Results
Pioglitazone improves plasma lipid levels and redox state in aging mice
Previous studies reported that apoE −/− mice were used as an atherosclerotic mice model because they were prone to severe hyperlipidemia and spontaneous atherosclerotic lesions in a time-dependent manner. In this study, during the aging process from 11-month to 15-month of age, Piog treatment diminished aggravating hypercholesterolemia, and 16 weeks of Piog treatment, plasma TC level was reduced compared to the control group (P < 0.01) (Fig. 1A) . For plasma TG level in mice, they were significantly decreased by Piog treatment both at 8-week and 16-week (P < 0.05), however, administration of Piog did not affect plasma Glu level in apoE −/− mice (Fig. 1B, C) .
Considering the anti-oxidative and anti-inflammatory properties of PPARγ agonist, we detected the redox and inflammatory status in circulation using the activities of SOD and MPO as the indicators, and found that Piog significantly increased plasma SOD activity, and decreased MPO activity, respectively (Fig. 1D, E) .
On the other hand, plasma ALT activity, creatinine level and body weight were evaluated the toxic effects of Piog in vivo, and no alterations were observed at the end of 4-month treatment between two groups of apoE −/− mice (Fig. 1F , G, H), showing no obvious toxicity to the liver, kidney and the whole body.
Pioglitazone attenuates aortic atherosclerosis
The impact of pioglitazone on the development of atherosclerosis in apoE −/− mice was assessed. Representative atherosclerotic lesions in cross-sections of aortic roots and en face aorta images stained with Oil Red O. The lipid staining area in the lesion of aortic sinus in the Piog group was smaller than that in the control mice (0.737 ± 0.107 mm 2 versus 0.849 ± 0.083 mm 2 ) (P < 0.05, Fig. 2A, B) . The en face analysis of pinned-out aortas revealed that the percent area of atherosclerotic lesion in the aging mice of Piog group was significantly reduced by about 24.8% compared to the vehicle mice (37.9% versus 50.4%, P < 0.01, Fig. 2C, D) .
Pioglitazone protects against aging-related renal injury
Kidney is one of the most sensitive organs during aging and histopathological changes in aging kidney were detected by Masson staining. Under the light microscope, Glomerulosclerosis, interstitial fibrosis and tubular atrophy were typically present in aging kidney in the vehicle group, the features included damaged basilar membrane, partial hyperplastic of interstitial fibrous tissues, broadened mesenchyme with accumulation of blue-stained collagenous fibers in Masson staining. Renal aging in Piog-treated mice showed obviously amelioration in the extent of glomerulosclerosis, interstitial fibrosis and tubular atrophy (Fig. 3A) . Furthermore, point counting of interstitial fibrosis (without including glomerulus) was performed and showed that Piog treatment obviously reduced the fibrosis (Piog group (5.76 ± 0.66) % versus control group (10.42 ± 1.02) %, P < 0.05, Fig. 3B) .
Meanwhile, SA-β-gal, as a reliable indicator of cell senescence, is present in the aging kidney even without morphologic changes (Debacq-Chainiaux et al., 2009 ), therefore, SA-β-gal staining was performed for assessing cell senescence in renal aging, the result showed that Piog significantly lowered SA-β-Gal positivity in renal frozen section (Piog group 25.14 ± 1.75 IOD/μm 2 versus control group 20.96 ± 1.59 IOD/μm 2 , P < 0.01) (Fig. 3C, D) . Combined the above results, it indicated that long-term Piog treatment protected kidney against aging-related disorders.
Pioglitazone improves the dermis in aging skin
The skin is one of the sensitive tissue in aging and age-related morphological changes of the skin were observed by HE staining. Fig. 1 . Quantitative analysis of plasma biochemical parameters and body weight in apoE −/− mice. The total cholesterol (A), triglycerides (B) and blood glucose (C) levels were measured at the indicated time. The enzyme activities of superoxide dismutase (SOD) (D), myeloperoxidase (MPO) (E) and alanine aminotransferase (ALT) (F), and plasma creatinine level (G) were measured using endpoint method. The results of two groups were analyzed by t-test and one-way ANOVA between the groups with different times. *P < 0.05, **P < 0.01 vs. vehicle group at 0-week. # P < 0.05, vs. vehicle group at the same time point. 
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Morphometric analyses of images taken from light microscopy also be used to determine the thickness of various skin layers. The epidermal thickness was measured from stratum basale to stratum granulosum, whereas the dermal thickness was the distance between the epidermis and the subcutaneous adipose layer. We found that skin aging appearance such as disruption of the extracellular matrix in the dermis, wrinkling, and laxity of the skin were improved, especially the thickness of the skin in the aged apoE −/− mice was increased in the Piog group, compared with the vehicle group (Fig. 4A ). Quantitative analysis of the skin thickness showed that the dermis containing collagen, elastic fibers, and hyaluronic acid was much thicker in the Piog group than that in the vehicle group (252.4 ± 37.0 μm versus 196.6 ± 24.1 μm, P < 0.01), even if the epidermis and adipose layer had no significant difference between two groups (Fig. 4B) .
Pioglitazone reduces hepatic steatosis and alters gene expression in liver
Genetic hyperlipidemia in apoE −/− mice could lead to significant hepatic steatosis, cirrhosis and impairment of systemic metabolism, thereby contributing to age-related diseases. We performed HE staining in liver slides and lipids extraction analysis to examine the effects of Piog on hepatic steatosis in apoE −/− mice, the results showed that lipid droplets vacuoles and morphological structure of hepatic parenchyma cells were obviously changed in Piog-treated mice compared to those of the vehicle mice (Fig. 4C) . Consistently, Piog significantly decreased hepatic TC, FC and TG levels in apoE −/− mice (Fig. 4D) .
To investigate the underlying mechanisms of Piog on aging-related disorders, we examined the effects of Piog on the hepatic mRNA expression of related genes involving in oxidation, inflammation, lipid D. Shen et al. Experimental Gerontology 102 (2018) 101-108 metabolism, and aging in apoE −/− mice by qPCR. As shown in Fig. 5A , accompanied with the up-regulation of hepatic PPARγ mRNA expression, Piog significantly increased anti-oxidative enzyme, PON1 mRNA level and decreased the mRNA levels of inflammatory factors TNFα and IL-6 in the liver. For lipoprotein-metabolism-related genes in apoE −/− mice, the mRNA levels of SR-BI, LXRα, ABCA1, ABCG8, and the bileacid-biosynthesis-related genes CYP7A1 and CYP27A1 were significant increased, while the mRNA level of FASN, a key enzyme in fatty acid synthesis, was markedly decreased, meanwhile, hepatic mRNA levels of Sirt1 and Klotho, as aging hallmarks genes, were also significantly increased in the Piog group, compared with the vehicle group (Fig. 5A) . Hepatic PPARγ and some protein levels were also measured. It showed that the key regulators of hepatic lipid metabolism, such as SR-BI, LXRα, ABCA1, and ABCG8 protein levels were significantly increased, while protein level of p53, a cell cycle protein was significantly lowered, which accompanied by elevated PPARγ protein level in Piogtreated mice, compared with the vehicle group (P < 0.01) (Fig. 5B) . The above data suggested that Piog had the beneficial effects of enhancing hepatic cholesterol transport and excretion into the bile, inhibiting fatty acid synthesis, and improving the oxidative and inflammation status in the liver.
Discussion
Pioglitazone, as a selective PPARγ agonist, is widely used in clinic for the treatment of type 2 diabetes mellitus (T2DM). In this study, we investigated the effects of Piog on aging phenotype and age-related disorders at the systems levels using the aged apoE −/− mice. Our results showed that Piog obviously improved signs of aging including body weight and skin atrophy, also significantly attenuated age-relative Hepatic expression of related genes involving in oxidation, inflammation, lipid metabolism. The mRNA levels (A) were determined qPCR and protein levels (B) were detected by Western blot. The data were analyzed by t-test. *P < 0.05 and **P < 0.01 vs. vehicle group.
D. Shen et al. Experimental Gerontology 102 (2018) 101-108 disorders such as aortic atherosclerosis, aging-related renal injury, and hepatic steatosis, the underlying mechanisms include the regulation of some key genes expression involving in lipid metabolism, anti-oxidation, inflammation and anti-aging molecules by activation of PPARγ signaling in apoE −/− mice.
The growing evidences showed that Piog, as a modulator of PPARγ signaling pathway, might be useful therapy for age-related diseases, including ameliorating renal injury in aging (Yang et al., 2009 ) and atherosclerosis following renal injury (Kim and Yang, 2013; Yamamoto et al., 2015) , recovering the memory of chronic cerebrovascular deficit (Nicolakakis et al., 2011) and delaying Alzheimer's disease (Crenshaw et al., 2015) , attenuating the hypertension-induced cognition decline (Lan et al., 2015) in several animal models. These previous studies on the therapeutic role of Piog often used higher doses and focused on a specific pathological model. In the present study, 11-month old apoE −/ − mice with dyslipidemia were selected for long-term (4 months) treatment of Piog, because the features of hyperlipidemia and high oxidative stress state in mice were similar to those of elderly population. Meanwhile, the dose of Piog is about 0.3 mg/mice per day, which relatively lower than those clinically used for T2DM. As we found, a series of age-related disorders as the systemic symptoms in arterial wall, kidney, liver and skin morphological features were observed in 15-month aged mice. Furthermore, the typical atherosclerotic lesions and hepatic steatosis were significantly decreased, renal aging described as glomerulosclerosis, interstitial fibrosis, tubular atrophy and cell senescence, and skin aging represented by the dermal thickness and structural disruption were also obviously reduced by Piog treatment in apoE −/− mice. This was the first systematic evidence from the whole organisms indicated that aging and age-related disorders could be ameliorated by low dose, long-term treatment of Piog in the aged apoE −/− mice.
It has been well established in mechanism that a progressive rise of oxidative stress and inflammation, accompanied with deregulated metabolism are the hallmarks of aging and many age-related diseases (Lopez-Otin et al., 2013) . Basically, the imbalance of redox metabolism can cause ROS accumulation, which leads to systemic inflammation, and play an important role in aging and age-related diseases (Finkel and Holbrook, 2000; Davalli et al., 2016) . Thus, we firstly investigated the role of Piog in regulating redox activity and inflammation in circulation. Extracellular SOD which participates in free radical detoxification is the main antioxidant enzyme that regulates circulating redox status (Abreu and Cabelli, 2010) . Elevated plasma MPO activity is a hallmark of neutrophil activation, which involved in the generation of ROS and tissue damage under the inflammatory stress state (van der Veen et al., 2009) . Our data showed that Piog significantly regulated anti-oxidative and anti-inflammation status of circulation by increased plasma SOD activity and decreased plasma MPO activity. We also observed that Piog could regulate the redox or inflammatory-related genes expression in liver. PON1 which mainly synthesized in the liver, is an HDL-located antioxidant enzyme (Marsillach et al., 2008) . Our previous study reported that hepatic expression of pro-inflammatory cytokines TNFα and IL-6 were inhibited by PPARγ activation (Du et al., 2016) . Here, we identified that Piog upregulated anti-oxidative PON1 expression and reduced the mRNA levels of TNFα and IL-6 in liver. Taken together, it is not surprising that the beneficial effects of Piog on anti-aging in apoE −/ − mice were attributed to its ability to modulate antioxidant defense and anti-inflammation.
Secondly, the considerable evidences indicated that Piog could regulate glucose and lipid metabolism with its safety and effectiveness in the clinical treatment of T2DM (Derosa and Maffioli, 2012) . Although the severe hypercholesterolemia of apoE −/− mice is spontaneously induced by genetic deficiency, our results showed that while the level of blood glucose did not change, Piog did diminished aggravating hypercholesterolemia, reduced plasma TG level, and ameliorated hepatic TC and TG accumulation. These findings suggest that lavage given of low-dose Piog can reduce aging-related disorders by regulation of lipid metabolism, but independent of glucose level, which is similar to Blalock's reports in rat model (Blalock et al., 2010) . Because that homeostasis of lipid metabolism is essential for the prevention of hepatic steatosis and atherosclerosis (Targher et al., 2010) , the liver is the central metabolic organ in the whole body, and PPARγ distributed in the liver was gradually reduced along with the aging process, we give an insight into hepatic gene expression of several well-established biomarkers of lipid metabolism under the Piog-treatment. Hepatic SR-BI, as a high-affinity HDL receptor, mediates cell selective uptake of CEs from spherical HDL, plays a critical role on reverse cholesterol transport (RCT) and its athero-protection in mouse models (Mineo and Shaul, 2012) . LXRα serves as a key regulator and intergrators of PPARγ in lipid metabolism and inflammation (Im and Osborne, 2011; Kidani and Bensinger, 2012) . ABC superfamily proteins, as the target genes of LXRα, are important membrane transporters that regulate the delivery of cholesterol. Hepatic ABCA1 plays an essential role in nascent HDL biogenesis by mediating the efflux of cell cholesterol to lipid poor apolipoprotein AI (apoAI), while ABCG8 is in charge of cholesterol excretion into the bile (Fitzgerald et al., 2010; Ji et al., 2012) . In addition, CYP7A1 and CYP27A1 are the key enzymes of bileacid synthesis, which promoting the secretion of cholesterol into bile, a role that is consistent with that of ABCG8.These lipoprotein-metabolism-related genes were reported as the targets of PPARγ or maybe upregulated by PPARγ through the formation of dimers with LXRα (Hamblin et al., 2009 ), our present findings support that the attenuation of aging-related disorders in aged apoE −/− mice are at least partly attributed to the alternation of lipid metabolism by PPARγ up-regulation, and the underlying mechanism of Piog on cholesterol metabolism involves in promoting cholesterol movement and HDL metabolism, via increasing SR-BI-dependent hepatic selective HDL-C uptake, ABCG8, CYP7A1 and CYP27A1-mediating excretion of cholesterol into the bile, as well as ABCA1-dependent secretion of nascent HDL. Besides the beneficial modulation in cholesterol metabolism, Piog could also reduce TG biosynthesis through decreasing mRNA expression of lipogenic gene FASN, and contribute to the amelioration of hepatic steatosis and atherosclerosis in aging process. Furthermore, we give attention to the role of Piog on the agingrelated genes, including Sirt1, Klotho and p53 in the liver. SIRT1 is a protein deacetylase reported to deacetylate both chromatin and nonhistone proteins, such as nuclear factor (NF)-κB, forkhead box class O (FOXO) 3, p53, LXR, PPARγ coactivator 1α (PGC-1α), has been proved to regulate critical metabolic pathways and physiological processes involved in cell growth and angiogenesis, apoptosis and senescence, stress response as well as maintenance of lipid metabolic homeostasis. Aging is characterized by declining SIRT1 activity and increased expression or activation of Sirt1 gene is demonstrated to prolonged lifespan (Houtkooper et al., 2012 ). The first-described non-histone deacetylation target for SIRT1 is p53, a cell cycle protein that considered as one of the hallmarks of replicative senescence involved in repression of DNA damage or oxidative stress (Luo et al., 2001 ). Klotho, a novel antiaging molecule with manifold effects, is also a downstream target of PPARγ. Depressed Klotho gene expression could increase the expression of aging-associated proteins, including β-galactosidase, p16, p21, and p53. Induction of Klotho expression may be a potential treatment for age-associated diseases (Kuro-o, 2009; Xu and Sun, 2015) . Our present results in the aged apoE −/− mice first confirm that the anti-aging mechanism of Piog is associated with raised Sirt1 and Klotho gene expression, and further decreased the p53 protein level, which mediated by activation of PPARγ. In summary, as prior reported that PPARγ might represent a critical mechanistic link between aging and stress or metabolic disturbances, our present study indeed demonstrates that in the aged apoE −/− mice, Piog as the activator of PPARγ signaling, has multiple beneficial modulation in the aging process and aged-related disorders of the whole body, including the amelioration of atherosclerosis, hepatic steatosis, aging-related renal injury and skin atrophy, which are linked to reduction of oxidative and inflammatory status in liver and plasma, regulation of lipid metabolism, inhibition of cell senescence. These findings provides new evidence at the systematic levels that the longterm and low-dosage of Piog may be a potential therapy in the development of aging and age-related diseases.
